BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» 'Unicorn' firm Wuxi Apptec granted listing approval in China in speedy seven weeks
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
'Unicorn' firm Wuxi Apptec granted listing approval in China in speedy seven weeks
April 4, 2018
By
Elise Mak
No Comments
HONG KONG – China's leading contract research organization (CRO), Wuxi Apptec Co. Ltd., is set to debut on the Shanghai Stock Exchange via a $910 million IPO for its core small-molecule CRO business.
BioWorld